Nanexa Dirección

Dirección controles de criterios 4/4

El CEO de Nanexa's es David Westberg , nombrado en Jan 2015, tiene una permanencia de 9.25 años. compensación anual total es SEK2.85M, compuesta por 78.4% salario y 21.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.27% de las acciones de la empresa, por valor de €20.52K. La antigüedad media del equipo directivo y de la junta directiva es de 9.3 años y 2.9 años, respectivamente.

Información clave

David Westberg

Chief Executive Officer (CEO)

kr2.8m

Compensación total

Porcentaje del salario del CEO	78.4%
Permanencia del CEO	9.3yrs
Participación del CEO	0.3%
Permanencia media de la dirección	9.3yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Westberg en comparación con los beneficios de Nanexa?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-kr71m
Dec 31 2023	kr3m	kr2m	-kr76m
Sep 30 2023	n/a	n/a	-kr43m
Jun 30 2023	n/a	n/a	-kr49m
Mar 31 2023	n/a	n/a	-kr55m
Dec 31 2022	kr3m	kr2m	-kr59m
Sep 30 2022	n/a	n/a	-kr54m
Jun 30 2022	n/a	n/a	-kr50m
Mar 31 2022	n/a	n/a	-kr42m
Dec 31 2021	kr2m	kr2m	-kr36m
Sep 30 2021	n/a	n/a	-kr31m
Jun 30 2021	n/a	n/a	-kr27m
Mar 31 2021	n/a	n/a	-kr25m
Dec 31 2020	kr3m	kr2m	-kr22m
Sep 30 2020	n/a	n/a	-kr19m
Jun 30 2020	n/a	n/a	-kr18m
Mar 31 2020	n/a	n/a	-kr13m
Dec 31 2019	kr2m	kr1m	-kr13m
Sep 30 2019	n/a	n/a	-kr12m
Jun 30 2019	n/a	n/a	-kr11m
Mar 31 2019	n/a	n/a	-kr12m
Dec 31 2018	kr2m	kr1m	-kr11m
Sep 30 2018	n/a	n/a	-kr9m
Jun 30 2018	n/a	n/a	-kr9m
Mar 31 2018	n/a	n/a	-kr8m
Dec 31 2017	kr1m	kr1m	-kr8m

Compensación vs. Mercado: La compensación total de David($USD262.07K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD406.04K).

Compensación vs. Ingresos: La compensación de David ha sido consistente con los resultados de la empresa en el último año.

CEO

David Westberg (63 yo)

9.3yrs

Permanencia

kr2,847,000

Compensación

Mr. David Westberg has been the Chief Executive Officer at Nanexa AB (publ) since 2015. Mr. Westberg serves as an Independent Director at Lipigon Pharmaceuticals AB (publ) since 2023. Mr. Westberg has expe...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Westberg	Chief Executive Officer	9.3yrs	kr2.85m	0.27% SEK 23.6k
Marten Rooth	Co-Founder	15.3yrs	sin datos	0.33% SEK 28.1k
Anders Johansson	Co-Founder & Head of Intellectual Property	15.3yrs	kr996.00k	0.30% SEK 26.1k
Björn Svanström	Chief Financial Officer	4.3yrs	sin datos	0.11% SEK 9.5k
Mikael Asp	Head of QA & Expert Sakkunnig	3.9yrs	sin datos	0.0027% SEK 230.1
Joel Hellrup	Head of Pharmaceutical R&D	no data	sin datos	0.0052% SEK 444.7

9.3yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 40M es experimentado (9.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Birgit Norinder	Independent Director	3yrs	kr180.00k	0.044% SEK 3.8k
Goran Ando	Independent Chairman of the Board	4.3yrs	kr260.00k	0.77% SEK 66.0k
Robert Gale	Member of Advisory Board - NEX-18	no data	sin datos	sin datos
Eva Nilsagard	Independent Director	3yrs	kr230.00k	0.13% SEK 11.4k
Magnus Westgren	Independent Director	9.3yrs	kr130.00k	0.19% SEK 16.1k
Axel Glasmacher	Member of Advisory Board - NEX-18 & NEX-20	no data	sin datos	sin datos
Richard Davis	Independent Director	1.9yrs	kr130.00k	sin datos
Kirsten Gronbaek	Member of Advisory Board - NEX-18	no data	sin datos	sin datos
Uwe Platzbecker	Member of Advisory Board - NEX-18	no data	sin datos	sin datos
Magnus Tobiasson	Member of Advisory Board - NEX-18	no data	sin datos	sin datos
Jose Miguel Diaz	Member of Advisory Board - NEX-18	no data	sin datos	sin datos
Xavier Leleu	Member of Advisory Board - NEX-20	no data	sin datos	sin datos

3.0yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de 40M se considera experimentada (3 años de antigüedad promedio).

Nanexa Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

High number of new directors

Recent updates

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

First quarter 2022 earnings released: kr0.24 loss per share (vs kr0.29 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanexa AB Announces That the Company's Preclinical Investigation

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

Forecast to breakeven in 2023

High number of new directors

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad